0001193125-14-024964.txt : 20140407 0001193125-14-024964.hdr.sgml : 20140407 20140128215607 ACCESSION NUMBER: 0001193125-14-024964 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20140128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 BUSINESS PHONE: 604-629-9223 MAIL ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 CORRESP 1 filename1.htm Correspondence

 

LOGO

 

Michael E. Tenta   VIA EDGAR AND FEDEX

T: +1 650 843 5636

mtenta@cooley.com

  

January 28, 2014

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jeffrey P. Riedler

Scot Foley

Bryan Pitko

Donald Abbott

Lisa Vanjoske

 

RE: Aquinox Pharmaceuticals, Inc. (f/k/a Aquinox Pharmaceuticals (USA) Inc.)

Confidential Draft Registration Statement on Form S-1

Confidentially Submitted November 18, 2013 and December 24, 2013

CIK No. 0001404644

Ladies and Gentlemen:

On behalf of Aquinox Pharmaceuticals, Inc. (“Aquinox” or the “Company”), we are submitting this letter and the following information in response to a letter, dated January 8, 2014, from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) with respect to the Company’s Confidential Draft Registration Statement on Form S-1 (the “Confidential Draft Registration Statement”), submitted on December 24, 2013. We are also electronically transmitting for filing a registration statement on Form S-1 (the “Registration Statement”) and sending the Staff a hard copy of this letter, the Registration Statement and a version of the Registration Statement that is marked to show changes to the Confidential Draft Registration Statement submitted on December 24, 2013. We are also separately sending the Staff a letter requesting confidential treatment of certain exhibits to the Registration Statement.

The numbering of the paragraphs below corresponds to the numbering of the comments in the letter. For the Staff’s convenience, we have incorporated your comments into this response letter in italics. Page references in the text of this response letter correspond to the page numbers in the Registration Statement. Capitalized terms used in this letter but otherwise not defined herein shall have the meanings ascribed to such terms in the Registration Statement.

FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM

LOGO

U.S. Securities and Exchange Commission

January 28, 2014

Page Two

 

Special Note Regarding Forward-Looking Statements and Industry Data, page 45

1. We note your response to Comment 14 and reissue the comment. Please revise your disclosure to remove the statement that you “have not independently verified any third-party information.”

In response to the Staff’s comment, the Company has revised the disclosure on page 46 to remove the statement that “[i]ndustry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified any third-party information. that the Company has “not independently verified any third-party information.”

Executive Compensation, page 110

2. In your next amendment, please revise your executive compensation disclosure to reflect the compensation awarded to named executive officers during the most recently completed fiscal year ended December 31, 2013. Please also note that your Summary Compensation Table should continue to include the compensation awarded to NEOs in the fiscal year ended December 31, 2012. Please refer to Instruction 1 to Item 402(n) of Regulation S-K.

In response to the Staff’s comment, the Company has revised its executive compensation disclosure on page 108 to reflect the compensation awarded to named executive officers during the most recently completed fiscal year ended December 31, 2013 and the fiscal year ended December 31, 2012.

***

Please contact me at (650) 843-5636 or Gordon Empey of Cooley LLP at (206) 452-8752 with any questions or further comments regarding our responses to the Staff’s comments.

Sincerely,

/s/ Michael E. Tenta

Michael E. Tenta

 

FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM

LOGO

U.S. Securities and Exchange Commission

January 28, 2014

Page Three

 

cc: David J. Main, Aquinox Pharmaceuticals, Inc.

Kamran Alam, Aquinox Pharmaceuticals, Inc.

Gordon Empey, Cooley LLP

Robin Mahood, McCarthy Tétrault LLP

Patrick A. Pohlen, Latham & Watkins LLP

Jim Morrone, Latham & Watkins LLP

Joseph Garcia, Blake, Cassels & Graydon LLP

Jim Barron, Deloitte LLP

 

FIVE PALO ALTO SQUARE, 3000 EL CAMINO REAL, PALO ALTO, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 WWW.COOLEY.COM

GRAPHIC 2 g619679g70d37.jpg GRAPHIC begin 644 g619679g70d37.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#@`C`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/?Z`,S4?$.E:4VR[O$23^X/F;\A2ND-)LH6_C?09Y`GVLQD M]#(A4?G1S(?*SH(Y$EC5XW5T89#*<@TR1U`!0`4`%`!0`4`CZOI] MI;QPM'--.TB< MVRA[FY7ADCZ*?0GUI.5AJ+9GVWQ$M&F5+VPGM5/\7WL?AP:.8?*=A!/%K6>L6OVBREWKG#`\,I]"*:=R6K''>./^1DT7ZC_`-#% M3+D?)$N:3?_P!JZ5;7_P!GD@%P@D6.3&X`],X]N::=UB&E= MF)X%T2WBTM-3F0275P2P=ADJN>WN>N:44.3Z'2ZCIEIJMH]M=Q*Z,,`XY4^H M/8T[7$G8X_P/?QPCPO\0(;>U)6TO, M#R\\`-QC\"*C9E[HE\'3+:S1L"X&=&L([>!)@P`WOY7+MW).:2:0--F)XHUG1M1F@OM+\R&]1LL MVS:&'8_4&DVN@TFMSMM3LAXF\)1D`>?)$LT9]'QG]>15[HE:,H^`=6-UICZ= M,<3VAP`>NS_ZQX_*E%A)6.4\7SMXO^).F^'(1OL[-P;@#H>[_DO'U-92]Z7* M>QAE]7PTJSW>WZ'K*J$4*H`4#``[5N>*'O%EEK%LBRRI#>`8>-CC)]5]133N)JQKW>HV5C"9;JYCB0=V;_.: M>Q-C$N)T\7^%;X6B%06*Q;NK%<$?3-3NBOA90\$:_;C3UTF[D$%S;DJHD.W< M,]/J/2B+Z#DNITFIZU8:3:-/Q*5SE?`UG->7>HZU<)M6 MY)5??)RV/;H*F/2YB6(#.\N,59%CA+:4^*O'L=Y;J?L5E@AR.H'3\S^E1NR]D2^./^1DT M7ZC_`-#%$MPCL6_B)823Z9;7L2Y^S.=_LIQS^8'YTY!%FGHE[HFL6$1 M'B+RAM'R8`V^W%42><>+)9/!?B'^W;9`89U8E.@+'JOYX-9R?+J=%"FZTE`= M\)M%E6RN_$=[EKK4'.QFZ[,Y)_%OY4J2ZL[:.4?,= M=8:?:Z7:+:V<0BB7G`[GU-5:Q&YEZSX0TO693-*C0W!ZR1'!/U'0TFDRE)HS MK3X=Z5!,)+B:>Y`_A8@`_7%+E0JM8B]RIJGAVSU>]MKJX:426WW`C`#KGGBDU<:=C4=%D1D=0RL M,$$9!%,1R=Y\/-*N)C);RS6V?X4(*CZ9Z5/*BN9E[1O!^EZ-,)XU::X7I)*< M[?H.@II)`Y-G04R3R?XAWI3;H!^)Q2;LKFM&DZM1074 M\[^%]A*\]QXGU!3).!6ESS%2WU_IFK5&(4`%`!0`4`%`!0`4`%`!0`4`%`!0` M4`%`'+^-/"4_BZTM[1=4^Q6\3[W40[]Y[?Q#&.?SJ)QYM#KPN)6';ERW9J1: M,MEIFGV5@Z0I9%=F]-P("D<@$*5@=6Z=EO8U:HQ/__9 ` end